Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Liabilities and Shareholders Equity (2023 - 2025)

Zenas BioPharma has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $383.6 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $383.6 million for Q4 2025, up 3.7% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 72.29% YoY), and the annual figure for FY2025 was $383.6 million, up 3.7%.
  • Liabilities and Shareholders Equity for Q4 2025 was $383.6 million at Zenas BioPharma, up from $322.0 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ZBIO hit a ceiling of $403.4 million in Q3 2024 and a floor of $68.2 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 3 years was $333.8 million (2025), compared with a mean of $310.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 442.63% in 2024 and later decreased 20.18% in 2025.
  • Zenas BioPharma's Liabilities and Shareholders Equity stood at $68.2 million in 2023, then surged by 442.63% to $370.0 million in 2024, then rose by 3.7% to $383.6 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $383.6 million (Q4 2025), $322.0 million (Q3 2025), and $293.1 million (Q2 2025) per Business Quant data.